Grand Pharmaceutical Group Ltd (HKG: 0512), a leading pharmaceutical company based in China, has announced a strategic partnership with MediTrust Health, an insurance, financing, and direct-to-patient pharmacy subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. This collaboration will focus on integrating Grand Pharma’s 90Y product into various commercial insurance schemes, aiming to benefit an estimated 25-30 million insured liver cancer patients. These patients will gain access to a medical insurance product with a reimbursement amount reaching “hundreds of millions renminbi.”
Grand Pharma’s SIR-Spheres, also known as Y-90 microsphere injection, is a targeted internal radionuclide therapy used for treating liver cancer with high doses. The product is recognized as the world’s only selective internal radiation therapy (SIRT) for colorectal cancer liver metastasis, as per the company’s press release. Grand Pharma acquired SIR-Spheres through the USD 1.4 billion acquisition of the Australian firm Sirtex Medical Ltd, which was completed in September 2018. First approved in the US in 2003 for the treatment of unresectable metastatic liver cancer and metastatic liver tumors from primary colorectal cancer, the medical device gained entry into the Hainan Boao Lecheng International Medical Tourism Pilot Zone in September 2021 through a special access scheme.- Flcube.com
